Professor of Medicine, University Pittsburgh
Hematology
Dr. Mark A. Socinski, MD
|
|
Give Review
Mark Socinski works in the field of Hematology. He researched medicine at University of Vermont College of Medicine. He has 2 awards "America's Top Doctors" and "America's Top Doctors for Cancer". Doctor Mark A. Socinski, MD is also published. He has 101 publications published. The lastest publication: "Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.' Doctor Mark A. Socinski, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung Cancer? The data suggest yes.
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung Cancer: a single-group, multicentre, phase 2 trial.
- Clinical considerations for the development of biosimilars in oncology.
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung Cancer (INSPIRE): an open-label, randomised,...
- A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small Cell lun...
- Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizum...
- Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBr...
- Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
- Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Pa...
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
- A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung Cancer with non-squamous histology with disease progression on bevacizumab conta...
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- Metastasis of Breast Carcinoma to the Maxillary Sinus.
- Erlotinib in African Americans with Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study with Genetic and Pharmacokinetic Analysis.
- Immunotherapy in lung Cancer.
- CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of adva...
- Temsirolimus therapy in a patient with lung adenoCarcinoma harboring an FBXW7 mutation.
- Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for A...
- RET Rearrangements in Lung AdenoCarcinoma and Radiation.
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Treatment of stage IV non-small cell lung Cancer: Diagnosis and management of lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practic...
- Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches.
- Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung Cancer.
- A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly...
- Validation of interobserver agreement in lung Cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung Cancer: the 2004 World Health Org...
- Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung Cancer: results of a phase I/II trial.
- Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung Cancer.
- The Impact of Local and Regional Disease Extent on Overall Survival in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Carcinoma.
- Differential pathogenesis of lung adenoCarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
- Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell L...
- Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung Cancer (NSCLC): A combined analysis of three phase 3 trials.
- Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall Cell lung carcinoma.
- A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ???70 Years) with Stage IIIB/IV ...
- Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung Cancer.
- ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
- Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung Cancer: results from the SALUTE trial.
- Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer.
- Maintenance therapy in advanced non-small cell lung Cancer: current status and future implications.
- Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung Cancer.
- Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage II...
- Personalized medicine in non-small-cell lung Cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
- Lung squamous Cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal Cell types.
- A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung Cancer.
- The emerging role of biomarkers in advanced non-small-cell lung Cancer.
- If histology matters...
- Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung Cancer.
- The many controversies of stage IIIA/IIIB lung Cancer.
- Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung Cancer: data from the randomized phase III INTEREST trial.
- Treatment of surgically resectable non-small-cell lung Cancer in elderly patients.
- Safety of bevacizumab in patients with non-small-cell lung Cancer and brain metastases.
- Fibroblastic growth factor pathway.
- Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung Cancer.
- Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small Cell lung...
- Carcinomatous meningitis in non-small-cell lung Cancer: response to high-dose erlotinib.
- Re-evaluating duration of therapy in advanced non-small-cell lung Cancer: is it really duration or is it more about timing and exposure?
- Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance p...
- A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung Cancer (NSCLC).
- Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung Cancer.
- Current treatments for advanced stage non-small cell lung Cancer.
- Treatment paradigms for advanced stage non-small cell lung Cancer in the era of multiple lines of therapy.
- Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung Cancer.
- Pemetrexed in relapsed small-cell lung Cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
- Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and pacli...
- Gefitinib versus docetaxel in previously treated non-small-cell lung Cancer (INTEREST): a randomised phase III trial.
- Gefitinib in advanced non-small cell lung Cancer: does it deserve a second chance?
- Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients ...
- The current status and evolving role of sunitinib in non-small cell lung Cancer.
- Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 pati...
- Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-sma...
- Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic Malignancies.
- Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carbo...
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung Cancer.
- The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung Cancer.
- Considerations for second-line therapy of non-small cell lung Cancer.
- Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung Cancer.
- Duration of first-line chemotherapy in advanced non small-cell lung Cancer: less is more in the era of effective subsequent therapies.
- Limited-stage small-cell lung Cancer: the current status of combined-modality therapy.
- Third-generation chemotherapy agents in the treatment of advanced non-small cell lung Cancer: a meta-analysis.
- Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung Cancer.
- Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung Cancer whose tumors have failed first-line platinum-based chemoth...
- Novel agents in the treatment of lung Cancer: Fourth Cambridge Conference.
- Antibodies to the epidermal growth factor receptor in non small cell lung Cancer: current status of matuzumab and panitumumab.
- Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung Cancer.
- Gene expression profiling reveals reproducible human lung adenoCarcinoma subtypes in multiple independent patient cohorts.
- Therapeutic advances in local-regional therapy for stage III non-small-cell lung Cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.
- Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung Cancer.
- Lung Cancer presenting with a solitary colon metastasis detected on positron emission tomography scan.
- Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung Cancer.
- Treatment of gefitinib-associated folliculitis.
- Combined modality therapy for stage III non-small cell lung Cancer.
- Current approaches to advanced-stage non-small-cell lung Cancer: first-line therapy in patients with a good functional status.
- Current and evolving treatment options for limited stage small cell lung Cancer.
- The emergence of a unique population in non-small cell lung Cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy.
- Concurrent chemoradiotherapy for unresectable stage III non-small cell lung Cancer.
- Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, an...
- The evolving role of pemetrexed (Alimta) in lung Cancer.
- Pemetrexed (Alimta) in small cell lung Cancer.
- Chemotherapeutic issues in the management of unresectable stage III non-small cell lung Cancer.
- Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung Cancer?
Schools
Univ Of Vt Coll Of Med
Beth Israel Hospital
Dana Farber Canc Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Beth Israel Deaconess Medical Center -
University of Vermont College of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1740341726 | |
| NPPES Provider LastName | SOCINSKI | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 275990001 | |
| NPPES Provider State | NC | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 237.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740341726 |
| Last Name Of The Provider | SOCINSKI |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Gurkamal S. Chatta, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Kirkwood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Redner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Vanderweele, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jocelyn L. Tan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vida A. Passero, MD
This Doctor is OpenDoctor Recommended.
|